Femtopath Citation Update-19
Title:High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients Authors:Wan-Ru Chao, Yi-Ju Lee, Ming-Yung Lee, Gwo-Tarng Sheu, and, Chih-Ping Han. Objective: Considering the clinical evidence of BRAF inhib...
Femtopath Citation Update-18
NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study AuthorsKuan-Jou Wu, Shu-Hao Li, Jia-Bin Liao, Chien-Chun Chiou, Chieh-Shan Wu,and Chien-Chin Chen BackgroundPurely cutaneous Rosai-Dorfman ...
Femtopath Citation Update-17
High frequency of BRAF mutations in mucinous ovarian carcinoma of Taiwanese patients AuthorsWan-Ru MD, PhD Chao, Yi-Ju Li, Ming-Yung PhD Lee, Gwo-Tarng PhD Sheu, and Chih-Ping Han BackgroundIn view of the encouraging clinical evidence of BR...
Femtopath Citation Update-16
Molecular characteristics of KRAS, BRAF, and PIK3CA mutation frequency in sessile serrated adenomas and polyps in patients from central Taiwan BackgroundColorectal cancer (CRC) is one of the most common cancers, and patients with CRC usuall...
Femtopath Citation Update-15
Extract of Pogostemon cablin Possesses Potent Anticancer Activity against Colorectal Cancer Cells In Vitro and In Vivo AuthorJu-Huei Chien, Shan-Chih Lee, Kai-Fu Chang, Xiao-Fan Huang, Yi-Ting Chen, and Nu-Man Tsai AbstractPogostemon cablin...
Femtopath Citation Update-14
Enhanced anticancer activity and endocytic mechanisms by polymeric nanocarriers of n‑butylidenephthalide in leukemia cells AuthorX.‑F. Huang, P.‑T. Chen, Y.‑L. Lin, M.‑S. Lee, K.‑F. Chang, K.‑W. Liao, G.‑T. Sheu, M.‑C. Hsieh and N.‑M. Tsai....
Femtopath citation update-13
Cedrol suppresses glioblastoma progression by triggering DNA damage andblocking nuclear translocation of the androgen receptor AuthorKai-Fu Chang, Xiao-Fan Huang, Jinghua Tsai Chang, Ya-Chih Huang, Jun-Cheng Weng and Nu-Man Tsai AbstractGli...
Femtopath citation update-12
Extract Derived from Cedrus atlantica Acts as an Antitumor Agent on Hepatocellular Carcinoma Growth In Vitro and In Vivo AuthorXiao-Fan Huang, Kai-Fu Chang, Shan-Chih Lee, Gwo-Tarng Sheu, Chia-Yu Li, Jun-Cheng Wenga, Chih-Yen Hsiao and Nu-M...
Femtopath citation update-11
Effects of Cedrus atlantica extract on acute myeloid leukemia cell cycledistribution and apoptosis AuthorPei‑Hsiu Hung, Ming‑Chang Hsieh, Shan‑Chih Lee, Xiao‑Fan Huang, Kai‑Fu Chang, Szu‑Yin Chen, Ming‑Shih Lee and Nu‑Man Tsai. AbstractThis...
Femtopath citation update-10
Suppression of oral cancer by induction of cell cycle arrest and apoptosis using Juniperus communis extract AuthorChing-Chang Lee, Chih-Yen Hsiao, Shan-Chih Lee, Xiao-Fan Huang, Kai-Fu Chang, Ming-Shih Lee, Ming-Chang Hsieh, and Nu-Man Tsai...
Femtopath citation update-9
Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression AuthorKai-Fu Chang, Xiao-Fan Huang, Jinghua Tsai Chang, Ya-Chih H...
Femtopath citation update-8
Pogostemon cablin Triggered ROS-Induced DNA Damage to Arrest Cell Cycle Progression and Induce Apoptosis on Human Hepatocellular Carcinoma In Vitro and In Vivo AuthorXiao-Fan Huang, Gwo-Tarng Sheu, Kai-Fu Chang, Ya-Chih Huang, Pei-Hsiu Hung...
Femtopath citation update-7
ArticleHigh frequency of BRAF mutations in mucinous ovarian carcinoma of Taiwanese patients Author Wan-Ru Chao, Yi-Ju Li, Ming-Yung Lee, Gwo-Tarng Sheu and Chih-Ping Han. Background In view of the encouraging clinical evidence of BRAF inhib...
Femtopath citation update-6
<Article> Antitumor Eects of N-Butylidenephthalide Encapsulated in Lipopolyplexs in Colorectal Cancer Cells <Author> Kai-Fu Chang, Jinghua Tsai Chang, Xiao-Fan Huang, Yu-Ling Lin, Kuang-Wen Liao, Chien-Wei Huang and Nu-M...
2019 BioAsia Poster_EGFR screen kit
肺癌血液中cfDNA EGFR突變監控_DIgital PCR應用分享
<Event> 2019 台北生技展 <Booth> 新光醫院精準醫療中心 <Speaker> 弘晉生技董事林鉅逵先生 <Topic> 肺癌病人用藥後血液EGFR突變監控
弘晉生技集團參展2019年BioAsia生技展
<Event> BioAsia <Date> 2019/07/25-2019/07/28 <參展廠商> 弘晉生技/弘晉有限公司/精專生醫/普羅王生技
Taiwan Biotech Exop 2018
<Event> Taiwan Biotech Exop 2018 <Date> 2018/07/19-2018/07/22 <booth> K906
<參展預告> 2018年台灣生技展 BioTaiwan Exhibition
<主題> 一年一度的台灣生技月_台灣生物科技大展將於2018年7月19日起一連四天開展了 弘晉生技今年將展出最新ddPCR產品,以及協力廠商普羅王生技的基因檢測服務。 <時間> 2018年7月19日起至7月22日 <地點> 台北市南港展覽館一館 <展位> K906
Femtopath citation update-5
<Title> Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non–Small Cell Lung Cancer with Multiple Driver Mutations <Abstract> Lung cancer is the leading cause of cancer deaths worldwide and i...
AccuQuant DIgital PCR launch at Medica 2017
<Event> New product launching – AccuQuant Digital PCR kit <Time> 2017. Nov. 13-16 <Booth location> Hall 3, J62 (TBG Biotech Corp)
Mutation enrichment方法學專利保護地區新增歐盟地區
狂賀!!! 弘晉生技研發生產相關的Mutation enrichment技術,繼臺灣、中國大陸、澳洲、美國之外,上個月也通過歐洲專利局的核可,獲得歐盟會員國的專利保護。
Femtopath EGFR mutation kit已正式啟動三級查驗登記臨床試驗收案
<Title> Femtopath EGFR mutation kit已正式啟動三級查驗登記臨床試驗收案 <Date> 2017/07/01 <Site> 1. 三軍總醫院 2. 馬偕紀念醫院(IRB已通過,收案時間待確認。) <Topic> 針對非小細胞肺癌患者(stage 3b/4),以手術檢體進行EGFR突變點測試。 Check our EGFR mutation kit
Taiwan Biotech Exop 2017
<Title> Taiwan Biotech Exop 2017 <Event> 馬偕紀念醫院 生醫發展中心 陳裕仁主任/醫師 蒞臨攤位指導
<活動預告> 弘晉生技將參展2017年台灣生物科技大展
<主題> 一年一度的台灣生技月_台灣生物科技大展將於2107年6月29日起一連四天開展了,弘晉生技今年也不缺席,將向國際B2B買家展示Femtopath mutation enrich Sanger/NGS dual system以及qPCR最新產品。 <時間> 2017年6月29日起至7月2日 <地點> 台北市南港展覽館4樓 N528
**國外媒體訪問** 台灣國際銀髮族暨健康照護展
<主題> 弘晉生技參加2107年台灣銀髮族暨健康展,獲邀東南亞三大媒體採訪,包含菲律賓Manila Bulletin/印尼Femina集團/泰國Innolab。本次參展主題說明大腸瘜肉切除後進行Braf基因突變檢測的臨床意義與對一班亞健康人的重要性。 <時間> 2017年6月15-18日 <地點> 台北市世貿一館D區0310攤位 <訪問照片>
Rydapt® (midostaurin, formerly PKC412), FDA approves new combination treatment for acute myeloid leukemia.
<FDA Release> The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combina...
國防醫學院微免所學術專題演講_生技求才系列
<演講邀請> 國防醫學院微免所學術專題演講_生技求才系列 <演講者> 產品經理 邱怡昌 Jimmy Chiu <主持人> 國防微免 莊依萍老師 <時間> 2017年3月3日 <題目> 1. 分享產品開發經驗,以及學術研究如成果如何轉換成商品。 2.學界與業界的差異
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
For third-generation inhibitor, limit of detection of EGFR T790M mutation must be reaching 0.1 to 0.01% . Femtopath now offer you more affordable and high sensitivity T790M mutation kit, especially in plasma cfDNA. &nb...
Femtopath citation update-4
<Journal> Human Genomics (2016) 10:40; (SCI Impact factor=3.385) <Title> The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma. <Abstract> Jayson GC et al. remarked in Lancet that nearly 100% of...
2016 Medica expo
中醫四診與基因診斷活動照片
<活動時間> 105年11月6日 <活動地點> 中國醫大中醫學院
Dual system for NGS and sanger sequencing
Femtopath launch a PCR enrichment system for dual system 1. Next generation sequencing Illumina platform ion torrent platform 2. Sanger sequencing Now you can download new DM
白血病之中西醫對話論壇_中醫四診與致癌基因篩檢
◎簡介: 白血病位居癌症發生率第十名,事先沒有任何預兆,一旦發病便來勢洶 洶,沒有早晚期之分,也無法開刀治療。白血病前期的治療包含支持性療法, 以及低或高強度的化學治療。當發展為白血病時,只能採用高強度化療合併骨髓移植,然而預後及臨床反應均不是很好。近期白血病的治療亦有一些標靶藥物的設計,某些藥物具有明顯的生命延長效果,然而大多需要終生服藥。意義不明的克隆性造血(clonal hematopoiesis of indeterminatepotential,CHIP)是指骨髓或...
Can myelodysplastic syndromes be prevented?
Can myelodysplastic syndromes be prevented? Since smoking is linked to the development of leukemia and myelodysplastic syndromes (MDS), not smoking can lower the risk of these diseases. Of course, nonsmokers are also less likely than smoker...
Femtopath citation update-3
<Title> Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms <Abstract> Kras mutation is a common phenomenon in many human neoplasms. We aimed to assess ...
Femtopath, a member of Canadian Chamber of Commerce in Taiwan
We are glad to announce that we are a member of of Canadian Chamber of Commerce in Taiwan. The Canadian Chamber of Commerce in Taiwan was established in 1983 by a group of Canadians in answer to the absence of official representation...
VISIT FEMTOPATH IN HALL 3, BOOTH J62, 2016 MEDICA, DUSSELDORF
FemtoPath will be setting up a booth at 2016 MEDICA, Dusseldorf We have several new kits were launched recently, such as 1. IDH1 mutation kit; 2. CALR mutation kit; 3. NGS enrich kits and etc. Welcome to visit us at: Hall #: 3 Booth #: J62 ...
<活動照片>醫療器材臨床試驗中心品質與競爭力提升計畫
<活動主旨> 醫療器材臨床試驗中心品質與競爭力提升計畫發表會與簽約儀式 <活動地點> 中山醫學大學附設醫院 <活動時間> 2016年7月18日 <照片>
The news of DTC Genetic Testing Services from PoloWang Biotech was published at Marketwired web
Congratulations to PoloWang Biotech Inc. has interviewed by MARKETWIRED. The news of DTC Genetic Testing Services from PoloWang was published on the MARKETWIRED's website. Full article is available at the link. Please welcome to contact us ...
Polowang Biotech displays DTC genetic testing services at COMPUTEX TAIPEI 2016
Polowang Biotech Inc., a direct-to-consumers (DTC) genetic testing company, display their Cloud genetic screening service system at Taipei Cloud Expo at COMPUTEX TAIPEI 2016. Polowang Biotech Inc. recently cooperates with HongJing Biotech ...
AACR Annual Meeting 2016 in New Oleans, April 16 – 20
Developing mutation specific antibodies for a screening tool is a hot potato in recent years. More and more publications and reference report the utility of mutation specific antibodies could be widely used in clinical diagnostics. Recently...
Exosomes and Liquid Biopsies ASIA April 7- 8, 2016 Taipei Taiwan
FemtoPath is at Exosomes and Liquid Biopsies ASIA April 7- 8, 2016 Taipei Taiwan. We are happy to introduce total solution for molecular diagnostics of liquid biopsies.
Circulating mutant DNA to assess tumor dynamics
<Title> Circulating mutant DNA to assess tumor dynamics <Abstract> The measurement of circulating nucleic acids has transformed the management of chronic viral infections such as HIV. The development of analogous markers ...
Singapore MedLab Asia Pacific Expo Invitation
Dear all, FemtoPath is at MedLab Expo Booth H57 in Singapore during Mar 22-24. Please welcome to visit us, we will be happy to introduce you our total solution for mutation screen kits.
Brochure download_cfDNA mutation screen kit
ras_DM-2
Brochure download_mutation screen total solution
MOU signed : HongJing Bio (FemtoPath) and Vishuo
HongJing Bio have recently signed an MOU with Vishuo combining both companies product line. The purpose of the cooperation is to strengthen and coordinate both companies respective efforts to provide better products to help cl...
A New RAS G12D Specific Antibody for Immunohistochemical FFPE Application
<Ttile> A New RAS G12D Specific Antibody for Immunohistochemical FFPE Application <Event> Femtopath/Genetex will attend 2016 AACR on April in New Orlean <Topic> Femtopath/Genetex show a specific RAS G12D antibody, which de...
Femtopath/Genonfire於數位時代進行訪談
訪談主題> Femtopath(弘晉生技)如何以現有資源與資料庫跨足物聯網世代(Bio-IOT) <照片>
MedLab expo_2016.Jan_Dubai
Driver and Passenger Mutations in Cancer
<Title> Driver and Passenger Mutations in Cancer <Author> Julia R. Pon and Marco A. Marra <Abstract> Next-generation sequencing has allowed identification of millions of somatic mutations and epigenetic changes in cancer ce...
Kras G12D mutation antibody
Kras G12D mutation was been validated by Femtopath Kras mutation IHC method: Roche Ventena, Optiview detection kit, Ab titration:1000X.
2015年工研院RPC計畫成果發表會
<時間> 2015年12月8日 <活動> 2015年工研院RPC計畫成果發表會 <內容> 由弘晉生技執行長林鉅逵先生分享過去與工研院生醫所 蔡秀娟副所長/陳廷碩組長 帶領的醫材團隊,輔導本公司進行RPC計畫所獲得的成果。
IVD試劑與新藥CRO聯合研討會
<時間> 2015年12月4日 <活動> IVD試劑與新藥CRO聯合研討會 <內容> 由馬偕醫院/工研院生醫與醫材所/佳生科技/弘晉生技共同舉辦的研討會 分享產官學界對於目前IVD產品規格製訂的經驗分享與現階段法規的討論
2015 IVD試劑與新藥CRO聯合研討會-醫療器材標準規範與臨床應用
<<網路報名連結>> ◎活動時間:104年12月4日(五) 8:00-12:30 ◎活動簡介: 衛生福利部食品藥物管理署自民國93年起推動「醫療器材採認標準制度」,至今公告採認918項國內外醫療器材標準以提供醫療器材業者進行產品安全與功效評估,並透過制定公告臨床前測試基準及體外診斷醫療器材技術基準,作為醫療器材查驗登記審查依據。 本活動說明我國醫療器材採認標準現況、並以實例說明應用醫療器材標準與法規指引於醫療器材產品開發與測試驗證。研討會的主題以新技...
<生醫人網摘介紹>弘晉生技基因檢測試劑與GenonFire行動醫療APP
生醫人網摘於104年10月28日專文介紹弘晉生物科技 專題報導公司目前營運產品與基因檢測服務 本公司目前已開發出行動醫療APP<Genonfire> 搭配APP服務模式,可以快速服務一般民眾了解自身基因資訊。 專題內文連結處
遠見雜誌專文介紹
弘晉生物科技股份有限公司獲得經濟部中小企業處頒發潛力育成廠商 遠見雜誌專文介紹弘晉生技公司 弘晉生物科技研發的特殊專利技術能在龐大野生型基因背景下,特異性的放大突變型基因以提高檢測靈敏度。應用於不同癌細胞比例的檢體類型(如福馬林固定-石蠟包埋檢體、細針抽取物、血液),以尋求對癌症患者最有益的治療方法。經工研院生醫所輔導進行產品的可行性驗證,現有產品包括FemtoPath EGFR Mutation Screen Kit及FemtoPath Multiplex K...
Approach 0.5% detection sensitivity with 200 reading depth
<Material and Method> 1. Femtopath enrichment method 2. Specific adaptor 3. Illumina NGS system <Data summary> 1. Raw data from “FemtoPath mutation enrichment assays” plus “Illumina MiSeq” can significantly locate mutations from...
舉行臨時股東會通知
日期: 104年10月19日 時間: PM6:30 其他:若需簡報資料,請來信索取。 [email protected]
EGFR positive rate(78.08%) is higher than Brand C (72.6%)
<Title> 高敏感度核酸定序分子診斷技術 <Author> 黃志凱 馬偕紀念醫院病理科 <Abstract> 大約35%非小細胞肺癌(non-small cell lung cancer;NSCLC)的患者具有 EGFR基因突變,並對EGFR 抑制劑,如 Tarceva具有高度的反應。醫生需要根據患者的分子檢測結果決定適合患者的治療方式。現今已有許多分子生物技術,如 HRM (HighResolution Melt) analys...
ASCO臨床腫瘤年會發表臨床試驗論文對大腸癌標靶治療 再次要求All-Ras的檢驗應該要陰性
<Title> Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor ReceptorMonoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion ...
醫材申請臨床試驗是提升產品系統與公司品牌的價值 (Design Control: 確認未來與現在的需求)
食藥署自102年起依據國內醫療器材產業發展趨勢,優先培育來自國內各大醫學中心相關科別(骨科、檢驗科、整形外科、心血管科、婦產科)之臨床試驗種子醫師,赴海外實地參與先進國家(美國、日本)之臨床試驗。期能經由早期介入高階醫療器材臨床試驗規劃及執行階段,通盤理解醫療器臨床試驗核心價值,並藉由相關產、學、研、醫界互動之過程,建立良好溝通橋樑,深化瞭解醫療器材臨床試驗產業上的創新價值,擴展國內醫療器材臨床試驗視野及強化跨國高階醫療器材研發合作量能,進而提升醫療器材產業全球化競爭力。 ...
弘晉生技和普羅王生技與交大規劃創立”ECOHORT 運聯網” 是CSR社會企業
敬愛的所長老師前輩同好朋友, 謝謝您今天參加交大生醫論壇籌備會,也謝謝您對演講內容的興趣與諸多指導。 弘晉生技和普羅王生技希望能夠和台灣年輕的創業精英,共同創造台灣下一波的經濟新藍海。也期待您十月十五日的光臨與指導。 第一階段ecohort, 創造廠商與外界最快最近距離最高效益的互動互聯網, 以協助廠商上市前修正, 第二階段產品廣告效益創意最佳化, 讓市場提前被碰撞被激發, 第三階段確實建立收費點, 各種器材進一步競逐關鍵節點, 並要讓上下軟硬人物互聯, 第四階段, 學生與廠...
未來cfDNA有專用採血管 保存期限大躍進
Sample-to-Sequence Triple Play Sequence ctcDNA (whole cells), cfDNA (cell fragments), and Germline DNA from a Single Blood Sample The advent of next-generation sequencing (NGS) has quickened the pace of discovery in oncology by making avail...
2015北京301免疫组织化学技术理论与应用培训
參考資料檔如下: https://www.dropbox.com/s/a346fkvnfffbo1n/2015%E4%B8%AD%E8%8F%AF%E9%86%AB%E5%AD%B8%E6%9C%83%E5%8C%97%E4%BA%AC301-%E6%AA%A2%E9%AB%94%E5%9B%BA%E5%AE%9A%E5%B0%8D%E5%88%86%E7%97%85%E7%9A%84%E5%BD%B1%E9%9F%BF.pdf?dl=0 https://www.dropbo...
Femtopath citation updated-2
<Title> Using low sensitivity of direct sequencing to detect K-ras mutations? A new method for improving diagnostic accuracy. <Author> Chi-Kuan Chen; Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan  ...
Femtopath citation updated-1
<Title> Identification of real-time PCR-negative EGFR mutations by direct sequencing test <Author> Tao-Yeuan Wang, Chi-Kuan Chen; Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan <Abstract> Background: Hig...
彰化基督教醫院周副院長/楊鴻明醫師/賴處長等拜訪
Femtopath submit a poster to APIAP, Korea, 2013.
We are honored to be able to participate on the 8th Asia Pacific IAP Congress on Busan, Korea. Sharing our technology on how we can improve the accuracy and sensitivity of cancer mutation detection. By using Femtopath mutation enrichment ki...
Abcam Epitomics’ new L858R specific antibody verified by Femtopath EGFR mutation kit
Abcam Epitomics’ new L858R specific antibody verified by Femtopath EGFR mutation kit. In past 2 years, Femtopath help Abcam-Epitomics to develop a new EGFR L858R specific antibody. Epitomics’ Dr. Aihua Li had posted the latest d...